Elicio Therapeutics (ELTX) Non-Current Debt (2020 - 2026)

Elicio Therapeutics (ELTX) has 4 years of Non-Current Debt data on file, last reported at $9.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt changed N/A year-over-year to $9.5 million; the trailing twelve-month figure through Mar 2026 stood at $9.5 million (changed N/A YoY), and the FY2025 full-year result was $9.4 million, down 53.04% from the prior year.
• Non-Current Debt for Q1 2026 stood at $9.5 million, up from $9.4 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $20.0 million in Q4 2024 and bottomed at $9.3 million in Q2 2025.
• The 3-year median for Non-Current Debt is $9.5 million (2026), against an average of $11.6 million.
• Peak annual rise in Non-Current Debt reached 53.04% in 2025, while the deepest fall reached 53.04% in 2025.
• A 3-year view of Non-Current Debt shows it stood at $20.0 million in 2024, then slumped by 53.04% to $9.4 million in 2025, then gained by 0.72% to $9.5 million in 2026.
• The last three Non-Current Debt figures came in at $9.5 million (Q1 2026), $9.4 million (Q4 2025), and $9.7 million (Q3 2025), per Business Quant data.

Peer Comparison